{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T18:22:00Z","timestamp":1794075720795,"version":"4.8.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-27147-x","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T16:15:35Z","timestamp":1765296935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Do cognitive tests capture symptoms that matter to people with Huntington\u2019s disease?"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9898-8327","authenticated-orcid":false,"given":"Cali M.","family":"Roiboit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7858-9183","authenticated-orcid":false,"given":"Jennifer R.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9637-8590","authenticated-orcid":false,"given":"Julie C.","family":"Stout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"27147_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"M Macdonald","year":"1993","unstructured":"Macdonald, M. et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington\u2019s disease chromosomes. Cell 72, 971\u2013983 (1993).","journal-title":"Cell"},{"key":"27147_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"FO Walker","year":"2007","unstructured":"Walker, F. O. Huntington\u2019s disease. Lancet 369, 218\u2013228 (2007).","journal-title":"Lancet"},{"key":"27147_CR3","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s00702-012-0787-x","volume":"119","author":"K Banaszkiewicz","year":"2012","unstructured":"Banaszkiewicz, K. et al. Huntington\u2019s disease from the patient, caregiver and physician\u2019s perspectives: three sides of the same coin? J. Neural Transm (Vienna). 119, 1361\u20131365 (2012).","journal-title":"J. Neural Transm (Vienna)"},{"key":"27147_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1037\/neu0000134","volume":"29","author":"CM Eddy","year":"2015","unstructured":"Eddy, C. M. & Rickards, H. E. Cognitive deficits predict poorer functional capacity in Huntington\u2019s disease: but what is being measured? Neuropsychology 29, 268\u2013273 (2015).","journal-title":"Neuropsychology"},{"key":"27147_CR5","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/mds.26012","volume":"29","author":"CA Ross","year":"2014","unstructured":"Ross, C. A. et al. Determinants of functional disability in Huntington\u2019s disease: role of cognitive and motor dysfunction. Mov. Disord. 29, 1351\u20131358 (2014).","journal-title":"Mov. Disord"},{"key":"27147_CR6","doi-asserted-by":"publisher","first-page":"e2395","DOI":"10.1212\/WNL.0000000000011893","volume":"96","author":"B McAllister","year":"2021","unstructured":"McAllister, B. et al. Timing and impact of psychiatric, cognitive, and motor abnormalities in Huntington disease. Neurology 96, e2395\u20132406 (2021).","journal-title":"Neurology"},{"key":"27147_CR7","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","volume":"79","author":"JS Paulsen","year":"2008","unstructured":"Paulsen, J. S. et al. Detection of Huntington\u2019s disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatry. 79, 874\u2013880 (2008).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"27147_CR8","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/mds.25997","volume":"29","author":"JS Paulsen","year":"2014","unstructured":"Paulsen, J. S. & Long, J. D. Onset of Huntington\u2019s disease: can it be purely cognitive? Move Disord. 29, 1342\u20131350 (2014).","journal-title":"Move Disord"},{"key":"27147_CR9","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1212\/01.WNL.0000098878.47789.BD","volume":"61","author":"AK Ho","year":"2003","unstructured":"Ho, A. K. et al. Profile of cognitive progression in early Huntington\u2019s disease. Neurology 61, 1702\u20131706 (2003).","journal-title":"Neurology"},{"key":"27147_CR10","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/arclin\/acx086","volume":"32","author":"JS Snowden","year":"2017","unstructured":"Snowden, J. S. The neuropsychology of Huntington\u2019s disease. Arch. Clin. Neuropsychol. 32, 876\u2013887 (2017).","journal-title":"Arch. Clin. Neuropsychol."},{"key":"27147_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1037\/a0020937","volume":"25","author":"JC Stout","year":"2011","unstructured":"Stout, J. C. et al. Neurocognitive signs in prodromal Huntington disease. Neuropsychology 25, 1\u201314 (2011).","journal-title":"Neuropsychology"},{"key":"27147_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.psychres.2010.04.030","volume":"178","author":"LJ Beglinger","year":"2010","unstructured":"Beglinger, L. J. et al. Earliest functional declines in Huntington disease. Psychiatry Res. 178, 414\u2013418 (2010).","journal-title":"Psychiatry Res."},{"key":"27147_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1212\/WNL.54.2.452","volume":"54","author":"K Marder","year":"2000","unstructured":"Marder, K. et al. Rate of functional decline in Huntington\u2019s disease. Neurology 54, 452\u2013452 (2000).","journal-title":"Neurology"},{"key":"27147_CR14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/18796397241293955","volume":"13","author":"J Petrillo","year":"2024","unstructured":"Petrillo, J. et al. Cognitive impairment in Huntington\u2019s disease and its impact on functioning: concept elicitation and cognitive debriefing for the Huntington\u2019s disease everyday functioning (Hi-DEF) scale. J. Huntingtons Dis. 13, 409\u2013569 (2024).","journal-title":"J. Huntingtons Dis."},{"key":"27147_CR15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3233\/JHD-160228","volume":"5","author":"JA Simpson","year":"2016","unstructured":"Simpson, J. A. et al. Survey of the Huntington\u2019s disease patient and caregiver community reveals most impactful symptoms and treatment needs. J. Huntingtons Dis. 5, 395\u2013403 (2016).","journal-title":"J. Huntingtons Dis."},{"key":"27147_CR16","unstructured":"Food, U. S. & Administration, D. The Voice of the Patient: Huntington\u2019s Disease.\u00a0https:\/\/fda.report\/media\/96196\/The-Voice-of-the-Patient--Huntington_s-Disease.pdf+%2Autf-8%27%27The-Voice-of-the-Patient--Huntington%25E2%2580%2599s-Disease.pdf (2016)."},{"key":"27147_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5334\/tohm.583","volume":"11","author":"MC Gornick","year":"2021","unstructured":"Gornick, M. C. et al. Huntington\u2019s disease community perspectives on desired characteristics of disease modifying therapies. Tremor Other Hyperkinet Mov. 11, 1\u20139 (2021).","journal-title":"Tremor Other Hyperkinet Mov."},{"key":"27147_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3233\/JHD-231520","volume":"13","author":"KE Anderson","year":"2024","unstructured":"Anderson, K. E. et al. What Huntington\u2019s disease patients say about their illness: an online Direct-to-Participant pilot study. J. Huntingtons Dis. 13, 237\u2013248 (2024).","journal-title":"J. Huntingtons Dis."},{"key":"27147_CR19","first-page":"4S","volume":"10","author":"RSE Keefe","year":"2013","unstructured":"Keefe, R. S. E. et al. Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials. Innov. Clin. Neurosci. 10, 4S\u201319S (2013).","journal-title":"Innov. Clin. Neurosci."},{"key":"27147_CR20","unstructured":"FDA. Early Alzheimer\u2019s Disease: Developing Drugs for Treatment Guidance for Industry.\u00a0https:\/\/www.fda.gov\/files\/drugs\/published\/Alzheimer%E2%80%99s-Disease---Developing-Drugs-for-Treatment-Guidance-for-Industy.pdf (2018)."},{"key":"27147_CR21","unstructured":"FDA. Alzheimer\u2019s Disease: Developing Drugs for the Treatment of Early Stage Disease. https:\/\/isctm.org\/public_access\/FDAGuidance_AD_Developing_Drugs_Early_Stage_Treatment.pdf (2013)."},{"key":"27147_CR22","unstructured":"FDA. Alzheimer\u2019s Disease: Developing Drugs for Treatment Guidance for Industry. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/Alzheimers-disease-developing-drugs-treatment-guidance-industy\u00a0(2020)."},{"key":"27147_CR23","unstructured":"FDA. Patient-Focused Drug Development: Collecting Comprehensive and Representative Input.\u00a0https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input (2021)."},{"key":"27147_CR24","unstructured":"FDA. Patient-Focused Drug Development: Methods to Identify What Is Important to Patients. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients\u00a0(2022)."},{"key":"27147_CR25","unstructured":"FDA. Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments.\u00a0https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome\u00a0(2022)."},{"key":"27147_CR26","unstructured":"FDA. Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints For Regulatory Decision-Making.\u00a0https:\/\/www.fda.gov\/media\/166830\/download (2023)."},{"key":"27147_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.14283\/jpad.2019.30","volume":"6","author":"CJ Edgar","year":"2019","unstructured":"Edgar, C. J., Vradenburg, G. & Hassenstab, J. The 2018 revised FDA guidance for early Alzheimer\u2019s disease: Establishing the meaningfulness of treatment effects. J. Prev. Alzheimers Dis. 6, 223\u2013227 (2019).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"27147_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/18796397251323549","volume":"14","author":"RL Fuller","year":"2025","unstructured":"Fuller, R. L. et al. Functional rating scale 2.0 (FuRST 2.0): A patient-reported outcome measure of function for Huntington\u2019s disease. J. Huntingtons Dis. 14, 171\u2013178 (2025).","journal-title":"J. Huntingtons Dis."},{"key":"27147_CR29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40120-023-00443-2","volume":"12","author":"DB DiBenedetti","year":"2023","unstructured":"DiBenedetti, D. B. et al. Technical review of clinical outcomes assessments across the continuum of Alzheimer\u2019s disease. Neurol. Ther. 12, 571\u2013595 (2023).","journal-title":"Neurol. Ther."},{"key":"27147_CR30","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1177\/2168479016689712","volume":"51","author":"MT Ropacki","year":"2017","unstructured":"Ropacki, M. T. et al. Clinically meaningful outcomes in early Alzheimer disease: A Consortia-Driven approach to identifying what matters to patients. Ther. Innov. Regul. Sci. 51, 380\u2013390 (2017).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"27147_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s41687-023-00595-7","volume":"7","author":"S Martin","year":"2023","unstructured":"Martin, S., Harris, N. & Romanus, D. Evaluating meaningful changes in physical functioning and cognitive declines in metachromatic leukodystrophy: a caregiver interview study. J. Patient Rep. Outcomes. 7, 70 (2023).","journal-title":"J. Patient Rep. Outcomes"},{"key":"27147_CR32","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3233\/JPD-225122","volume":"13","author":"JR Mammen","year":"2023","unstructured":"Mammen, J. R. et al. Mapping relevance of digital measures to meaningful symptoms and impacts in early Parkinson\u2019s disease. J. Parkinsons Dis. 13, 589\u2013607 (2023).","journal-title":"J. Parkinsons Dis."},{"key":"27147_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00415-024-12789-0","volume":"272","author":"JR Mammen","year":"2025","unstructured":"Mammen, J. R. et al. Longitudinal qualitative assessment of meaningful symptoms and relevance of WATCH-PD digital measures for people with early Parkinson\u2019s. J. Neurol. 272, 1\u201320 (2025).","journal-title":"J. Neurol."},{"key":"27147_CR34","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/mds.25964","volume":"29","author":"JC Stout","year":"2014","unstructured":"Stout, J. C. & HD-CAB: A cognitive assessment battery for clinical trials in Huntington\u2019s disease1,2,3. Mov. Disord. 29, 1281\u20131288 (2014).","journal-title":"Mov. Disord"},{"key":"27147_CR35","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/02770903.2016.1201835","volume":"54","author":"JR Mammen","year":"2017","unstructured":"Mammen, J. R. et al. Perceptions and experiences underlying self-management and reporting of symptoms in teens with asthma. J. Asthma. 54, 143\u2013152 (2017).","journal-title":"J. Asthma"},{"key":"27147_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/cea.13751","volume":"51","author":"JR Mammen","year":"2021","unstructured":"Mammen, J. R. et al. A mixed-methods analysis of younger adults\u2019 perceptions of asthma, self-management, and preventive care: \u2018This isn\u2019t helping me none\u2019. Clin. Exp. Allergy. 51, 63\u201377 (2021).","journal-title":"Clin. Exp. Allergy"},{"key":"27147_CR37","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/mds.870110204","volume":"11","author":"Huntington Study Group","year":"1996","unstructured":"Huntington Study Group. Unified Huntington\u2019s disease rating scale: reliability and consistency. Mov. Disord. 11, 136\u2013142 (1996).","journal-title":"Mov. Disord"},{"key":"27147_CR38","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","volume":"21","author":"SJ Tabrizi","year":"2022","unstructured":"Tabrizi, S. J. et al. A biological classification of Huntington\u2019s disease: the integrated staging system. Lancet Neurol. 21, 632\u2013644 (2022).","journal-title":"Lancet Neurol."},{"key":"27147_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.29.1.1","volume":"29","author":"I Shoulson","year":"1979","unstructured":"Shoulson, I. & Fahn, S. Huntington disease: clinical care and evaluation. Neurology 29, 1\u20131 (1979).","journal-title":"Neurology"},{"key":"27147_CR40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/mdc3.13661","volume":"10","author":"S Hughes","year":"2023","unstructured":"Hughes, S. et al. Development and psychometric properties of a new Brief, yet Comprehensive, behavioral questionnaire for Huntington\u2019s disease. Mov. Disord Clin. Pract. 10, 427\u2013433 (2023).","journal-title":"Mov. Disord Clin. Pract."},{"key":"27147_CR41","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/B978-0-323-95672-7.00015-7","volume-title":"Huntington\u2019s Disease","author":"BR Leavitt","year":"2024","unstructured":"Leavitt, B. R. Chapter 24 - Current clinical trials of new therapeutic agents for Huntington\u2019s disease. In Huntington\u2019s Disease (eds Yang, X. W. et al.) 571\u2013589 (Academic, 2024)."},{"key":"27147_CR42","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ijnurstu.2015.12.011","volume":"58","author":"JR Mammen","year":"2016","unstructured":"Mammen, J. R. et al. New approaches to qualitative interviewing: development of a card sort technique to understand subjective patterns of symptoms and responses. Int. J. Nurs. Stud. 58, 90\u201396 (2016).","journal-title":"Int. J. Nurs. Stud."},{"key":"27147_CR43","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3233\/JPD-225068","volume":"13","author":"JR Mammen","year":"2023","unstructured":"Mammen, J. R. et al. Relative meaningfulness and impacts of symptoms in people with Early-Stage Parkinson\u2019s disease. J. Parkinsons Dis. 13, 619\u2013632 (2023).","journal-title":"J. Parkinsons Dis."},{"key":"27147_CR44","doi-asserted-by":"crossref","unstructured":"Braun, V. & Clarke, V. Thematic Analysis: a Practical Guide (SAGE Publications Ltd, 2022).","DOI":"10.1007\/978-3-319-69909-7_3470-2"},{"key":"27147_CR45","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/2168479018772569","volume":"53","author":"E Richardson","year":"2019","unstructured":"Richardson, E. et al. Developing and implementing performance outcome assessments: Evidentiary, Methodologic, and operational considerations. Ther. Innov. Regul. Sci. 53, 146\u2013153 (2019).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"27147_CR46","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1177\/2168479017719934","volume":"51","author":"CJ Edgar","year":"2017","unstructured":"Edgar, C. J. Use of qualitative data to support content validity of Performance-Based cognitive outcome assessments. Ther. Innov. Regul. Sci. 51, 671\u2013671 (2017).","journal-title":"Ther. Innov. Regul. Sci."},{"key":"27147_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s41687-023-00644-1","volume":"7","author":"Z Zupan","year":"2023","unstructured":"Zupan, Z. Cognitive performance outcomes: considerations for drug development. J. Patient Rep. Outcomes. 7, 102 (2023).","journal-title":"J. Patient Rep. Outcomes"},{"key":"27147_CR48","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1080\/13854046.2017.1400105","volume":"32","author":"DL Rosado","year":"2018","unstructured":"Rosado, D. L. et al. Neuropsychological feedback services improve quality of life and social adjustment. Clin. Neuropsychol. 32, 422\u2013435 (2018).","journal-title":"Clin. Neuropsychol."},{"key":"27147_CR49","doi-asserted-by":"publisher","first-page":"e14363","DOI":"10.1002\/alz.14363","volume":"21","author":"LW Shaughnessy","year":"2025","unstructured":"Shaughnessy, L. W. & Weintraub, S. The role of neuropsychological assessment in the evaluation of patients with cognitive-behavioral change due to suspected Alzheimer\u2019s disease and other causes of cognitive impairment and dementia. Alzheimers Dement. 21, e14363 (2025).","journal-title":"Alzheimers Dement."},{"key":"27147_CR50","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/mds.20739","volume":"21","author":"AK Ho","year":"2006","unstructured":"Ho, A. K., Robbins, A. O. G. & Barker, R. A. Huntington\u2019s disease patients have selective problems with insight. Mov. Disord. 21, 385\u2013389 (2006).","journal-title":"Mov. Disord"},{"key":"27147_CR51","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/13803390600718958","volume":"29","author":"KF Hoth","year":"2007","unstructured":"Hoth, K. F. et al. Patients with Huntington\u2019s disease have impaired awareness of cognitive, emotional, and functional abilities. J. Clin. Exp. Neuropsychol. 29, 365\u2013376 (2007).","journal-title":"J. Clin. Exp. Neuropsychol."},{"key":"27147_CR52","doi-asserted-by":"publisher","first-page":"e0126773","DOI":"10.1371\/journal.pone.0126773","volume":"10","author":"F Solca","year":"2015","unstructured":"Solca, F. et al. Counterfactual thinking deficit in Huntington\u2019s disease. PLoS One. 10, e0126773 (2015).","journal-title":"PLoS One"},{"key":"27147_CR53","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3109\/10582452.2015.1132027","volume":"23","author":"K Kuppens","year":"2015","unstructured":"Kuppens, K. et al. Do illness perceptions in patients with fibromyalgia differ across countries? A comparative study. MYOPAIN 23, 13\u201320 (2015).","journal-title":"MYOPAIN"},{"key":"27147_CR54","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3233\/JHD-190380","volume":"8","author":"KE Anderson","year":"2019","unstructured":"Anderson, K. E. et al. Quality of care for Huntington\u2019s disease in the united states: findings from a National survey of patients and caregivers. J. Huntingtons Dis. 8, 509\u2013519 (2019).","journal-title":"J. Huntingtons Dis."},{"key":"27147_CR55","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3233\/JHD-140115","volume":"3","author":"NE Carlozzi","year":"2014","unstructured":"Carlozzi, N. E. et al. Understanding the outcomes measures used in Huntington disease pharmacologicaltrials: A systematic review - PMC. J. Huntingtons Dis. 3, 233\u2013252 (2014).","journal-title":"J. Huntingtons Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27147-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27147-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27147-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:01:52Z","timestamp":1765483312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-27147-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["27147"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-27147-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Professor Stout has consulted and served advisory boards for several sponsors and clinical trials\u202fover the past 20 years and is a director of a contract research organisation that facilitates the implementation of cognitive assessments in HD clinical trials. Professor Stout has been funded by the CHDI Foundation for projects aimed at developing a cognitive assessment battery for HD clinical trials. Professor Stout provides consultation services for HD clinical trials via Stout Neuropsych Pty Ltd, and is a director of Zindametrix Pty Ltd, which facilitates the implementation of the HD-CAB in clinical trials.\u202fAssociate Professor Jennifer R Mammen\u202fhas consulted for and\/or received research support from The Michael J Fox Foundation for Parkinson\u2019s Research, Critical Path for Parkinson\u2019s, National Institutes of Health\/NINR, Sigma Theta Tau International, and Lundbeck.\u202fAssociate Professor Jamie L Adams\u202fhas received research support from the Michael J. Fox Foundation for Parkinson\u2019s Research, Critical Path for Parkinson\u2019s, NIH\/NINDS, Biogen, the Huntington Study Group, and PhotoPharmics; received compensation as a consultant\/steering committee\/advisory board member from the Huntington Study Group, the Parkinson Study Group, AbbVie, VisualDx, BioSensics, Sana Biotechnology, Neuron23, Lundbeck, Biohaven, and the Michael J. Fox Foundation for Parkinson\u2019s Research; received honoraria for speaking from the Huntington Study Group, the Parkinson Study Group, and American Neurological Association. Both Associate Professors Jennifer Mammen and Jamie Adams have received research funding from the U.S. Food and Drug Administration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval for this study was provided by the Monash University Human Research Ethics Committee (MUHREC ID: 36930).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided written informed consent prior to participating in any study activities.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants provided written informed consent for their de-identified data to be used for research purposes.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"43609"}}